• Arcutis Biotherapeutics presented new INTEGUMENT-INFANT results for Zoryve cream 0.05% at the ACAAI annual meeting on Nov. 13, 2026.
• Caregivers reported reduced itching, improved eczema symptoms and better quality of life for infants with mild to moderate atopic dermatitis.
• The trial enrolled 101 infants; treatment was well tolerated, with no serious adverse events or severe treatment-emergent adverse events reported.
• An application to expand use to infants aged 3-24 months is under FDA review, with a February 23, 2027, decision target.
• Zoryve cream 0.05% is already approved in the U.S. for mild to moderate atopic dermatitis in children aged 2-5 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130900PRIMZONEFULLFEED9877009) on November 13, 2026, and is solely responsible for the information contained therein.